Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).-MedSci.cn

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

Krop, IE; Masuda, N; Mukohara, T; Takahashi, S; Nakayama, T; Inoue, K; Iwata, H; Toyama, T; Yamamoto, Y; Hansra, DM; Takahashi, M; Osaki, A; Koyama, K; Inoue, T; Yonekura, T; Mostillo, J; Ohwada, S; Tanaka, Y; Sternberg, DW; Yonemori, K

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务